Genocea Biosciences Inc (GNCAQ)

[wplong89]

Members of GNCA speaking at The 16th annual World Vaccine Congress March 29th-March 31st

Dr Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences, Inc.
17:40 3/30/2016 "Panel: The future combination cancer immunotherapies with vaccines, checkpoint inhibitors and oncolytic viruses"
11:30 3/31/2016 "Smarter identification of T cell antigens from infectious disease to cancer"

Dr Seth Hetherington, Chief Medical Officer, Genocea Biosciences
17:10 3/30/2016 "Positive top-line Phase II data for genital herpes immunotherapy"

Dr George Siber, CSO of ClearPath Vaccines & Scientific Advisory Board of Genocea, ClearPath Vaccines
9:00 3/30/2016 "Chair’s opening remarks"